Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Bartlett, E. J. Articles by Schiffer, W. Search for Related Content PubMed Citation Articles by Bartlett, E. J. Articles by Schiffer, W.

Effect of a Haloperidol Challenge on Regional Brain Metabolism in Neuroleptic-Responsive and Nonresponsive Schizophrenic Patients

OBJECTIVE: The CNS metabolic response to a neuroleptic challenge in treatment-responsive and nonresponsive schizophrenic patients was measured in order to examine the relation between treatment outcome and the capacity to alter neurochemical function in response to acute receptor blockade. METHOD: Positron emission tomography (PET) and [¹⁸F]fluorodeoxyglucose (FDG) were used to measure regional cerebral metabolism in seven schizophrenic patients judged to have been responsive to drug treatment previously and seven nonresponsive schizophrenic patients after a drug-free period of at least 3 weeks (baseline) and again 12 hours after administration of 5.0 mg of haloperidol. RESULTS: The haloperidol challenge caused widespread decreases in absolute metabolism in the nonresponsive patients but not the responsive patients. These group differences reflect the findings on the second (challenge) scans, since metabolic values at baseline were not statistically different in the two groups. The pattern of decreased metabolic activity in the nonresponders after the haloperidol challenge is similar to that previously observed in normal subjects. CONCLUSIONS: The metabolic response to drug challenge separates treatment responders from nonresponders and normal subjects. The results suggest that subtyping of schizophrenia (and other psychiatric disorders) can be achieved by measuring the physiologic response to a pharmacologic challenge in vivo with chemical brain-imaging techniques.

This article has been cited by other articles:

				V. Molina, J. Sanz, S. Reig, R. Martinez, F. Sarramea, R. Luque, C. Benito, J. D. Gispert, J. Pascau, and M. Desco Hypofrontality in men with first-episode psychosis The British Journal of Psychiatry, March 1, 2005; 186(3): 203 - 208. [Abstract] [Full Text] [PDF]

				D. J. Lang, L. C. Kopala, R. A. Vandorpe, Q. Rui, G. N. Smith, V. M. Goghari, J. S. Lapointe, and W. G. Honer Reduced Basal Ganglia Volumes After Switching to Olanzapine in Chronically Treated Patients With Schizophrenia Am J Psychiatry, October 1, 2004; 161(10): 1829 - 1836. [Abstract] [Full Text] [PDF]

				E T C Ngan, C J Lane, T J Ruth, and P F Liddle Immediate and delayed effects of risperidone on cerebral metabolism in neuroleptic naive schizophrenic patients: correlations with symptom change J. Neurol. Neurosurg. Psychiatry, January 1, 2002; 72(1): 106 - 110. [Abstract] [Full Text] [PDF]

				V. A. Curtis, J. van Os, and R. M. Murray The Kraepelinian Dichotomy: Evidence From Developmental and Neuroimaging Studies J Neuropsychiatry Clin Neurosci, August 1, 2000; 12(3): 398 - 405. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 1998 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us